NASDAQ:LRMR

Larimar Therapeutics Stock News

etoro logo Buy LRMR
*Your capital is at risk
$4.11
+0.130 (+3.27%)
At Close: Aug 04, 2026
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $1
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an

2 Breakout Stocks to Buy Immediately

12:00pm, Sunday, 08'th Mar 2026
Tom Yeung here with your Sunday Digest .  In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
Guru Stock PicksKen Fisher has made the following transactions:Reduce in DEO by 23.8%Sold out in VSHAdd in AMKR by 204.55%New position in BROChuck Royce has mad
Stock News Hormuz disruption risks energy shock: Exxon Mobil (XOM) and global markets face rising supply risks as Iran claims to have shut the Strait of Hormuz;
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook.
The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know.
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communi
Oncology Pharma (OTCMKTS:ONPH - Get Free Report) and Larimar Therapeutics (NASDAQ: LRMR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich's Ataxia's ro
Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE